In short
Clinical trials investigating AAV9-CTNT-COBAG3 are studying an interventional gene-based treatment in adults with BAG3-associated dilated cardiomyopathy. The trials aim to assess safety, tolerability, and possible clinical benefit after a single intravenous infusion. The target population is adult participants with this inherited heart condition.
Key points
- AAV9-CTNT-COBAG3 is being studied in an early Phase 1/2 clinical trial for adults with BAG3-associated dilated cardiomyopathy. The trial is authorised and plans to enroll 18 participants. Part A focuses on safety and tolerability after a single intravenous infusion, while Part B looks at possible clinical benefit compared with an external control. The main safety measures include treatment-emergent adverse events, serious adverse events, physical exams, vital signs, laboratory tests, and ECG results. This trial is designed to learn whether the treatment can be given safely and whether it may help people with this inherited heart condition.
Trial overview
The listed study is an interventional Phase 1/2 trial of AAV9-CTNT-COBAG3 in adults with BAG3-associated dilated cardiomyopathy. It is authorised and plans to enroll 18 participants.
The trial title names ALXN2350, while the provided data also lists AAV9 as an intravenous intervention in the study. The study is focused on an inherited heart condition linked to a BAG3 mutation.
Who can participate
The target population is adult participants with BAG3-associated dilated cardiomyopathy. No other age groups or conditions are described in the source data.
This means the study is not described as a general heart failure trial, but as a trial for a specific genetic form of dilated cardiomyopathy.
Study design and phases
This is an interventional study, which means the research team gives a treatment and then measures what happens. The study is in Phase 1/2, so it is early in development and is designed to first study safety and then look for possible benefit.
According to the brief summary, Part A is designed to determine safety and tolerability after a single intravenous infusion of ALXN2350 in participants with BAG3-associated DCM. Part B is designed to evaluate clinical impact, meaning whether there are signs that the treatment may help, compared with an external control.
What is being measured
The primary outcome for Part A is the incidence and severity of treatment-emergent adverse events and serious adverse events. In simple terms, the study checks how often health problems happen after treatment and how severe they are.
The trial also records clinically significant safety findings from physical examinations, vital sign measurements, clinical laboratory assessments, and ECG results. These tests help researchers see whether the treatment affects the body or heart in important ways.
Treatment and comparison plan
The study description says participants receive a single intravenous infusion of ALXN2350 in Part A. The intervention list also includes AAV9 given by intravenous use, along with several oral medicines such as Rapamune, prednisone, and co-trimoxazole.
For Part B, the trial compares clinical impact against an external control. An external control means the results are compared with data from another group outside the treatment arm rather than from people in the same study who receive a different treatment.
What the trial means for patients
This trial is aimed at a small group of adults with a rare inherited heart disease. Because it is early-stage, the main question is whether the study treatment can be given safely and whether there are early signs of benefit.
For patients, the most important point is that the study is not yet a confirmed treatment standard; it is research designed to learn more about AAV9-CTNT-COBAG3 in BAG3-associated dilated cardiomyopathy.